Product Pipeline


Marketed Product

Under a development and commercialization agreement established with Novartis Pharma AG, Idenix co-developed and co-launched the licensed hepatitis B drug candidate, telbivudine, which is sold on the market as Tyzeka®/Sebivo®. Novartis AG now has full commercialization rights to Tyzeka/Sebivo, and Idenix receives royalty payments on product sales.




At Idenix, our corporate values — Innovation, Teamwork, Respect, Quality and Ownership — reflect a unique and dynamic culture.